Recurrent Osteosarcoma: Clinical Trials

22 trials for Recurrent Osteosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed. 22 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 222Completed 22
Phase 13Completed 3

Follow Recurrent Osteosarcoma: new trials by email Literature Review of Recurrent Osteosarcoma trials Research Report on Recurrent Osteosarcoma

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2CompletedNational Cancer Institute (NCI)232018-08-132026-04-03
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma
Phase 1 / Phase 2CompletedChildren's Oncology Group262018-01-312024-07-15
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)182017-11-282026-04-21
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)202017-11-132026-04-13
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)62017-09-142024-12-11
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Osteosarcoma
Phase 2CompletedNational Cancer Institute (NCI)222016-02-162022-01-18
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Phase 2CompletedNational Cancer Institute (NCI)412016-02-042023-10-26
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Denosumab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Osteosarcoma, Recurrent Osteosarcoma
Phase 2CompletedChildren's Oncology Group562015-11-212024-01-22
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)1402015-03-302023-10-17
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis - Adult Liposarcoma, Metastatic Liposarcoma
Phase 2CompletedNorthwestern University1782015-03-212022-06-07
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Eribulin Mesylate, Pharmacological Study - Recurrent Osteosarcoma
Phase 2CompletedNational Cancer Institute (NCI)192014-08-012020-05-19
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma
Phase 2CompletedNational Cancer Institute (NCI)462012-06-182018-12-11
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Phase 2CompletedChildren's Oncology Group1182011-02-012020-05-13
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)782010-06-012018-08-15
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1782009-11-012015-07-30
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
therapeutic angiotensin-(1-7), laboratory biomarker analysis - Bone Cancer, Chondrosarcoma
Phase 2CompletedWake Forest University Health Sciences202009-10-012018-07-05
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1162009-01-012015-03-30
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
sorafenib tosylate, therapeutic conventional surgery, laboratory biomarker analysis - Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma
Phase 2CompletedNational Cancer Institute (NCI)152006-06-012014-04-30
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
ixabepilone - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1202006-04-012014-11-14
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
oxaliplatin - Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Phase 2CompletedNational Cancer Institute (NCI)1802004-10-012013-06-05

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Osteosarcoma (22)  ·  Neuroectodermal Tumors, Primitive, Peripheral (13)  ·  Sarcoma (12)  ·  Neuroblastoma (11)  ·  Rhabdomyosarcoma (9)  ·  Hepatoblastoma (7)  ·  Wilms Tumor (6)  ·  Lymphoma, Non-Hodgkin (5)  ·  Medulloblastoma (5)  ·  Ependymoma (4)  ·  Familial ependymoma (4)  ·  Glioma (4)  ·  Histiocytosis, Langerhans-Cell (4)  ·  Rhabdoid Tumor (4)  ·  Sarcoma, Ewing (4)

Broader conditions

Neoplasms (22)  ·  Neoplasms by Histologic Type (22)  ·  Neoplasms, Bone Tissue (22)  ·  Neoplasms, Connective Tissue (22)  ·  Neoplasms, Connective and Soft Tissue (22)  ·  Neoplasms, Germ Cell and Embryonal (14)  ·  Neoplasms, Glandular and Epithelial (14)  ·  Neoplasms, Nerve Tissue (14)  ·  Neoplasms, Neuroepithelial (14)  ·  Neuroectodermal Tumors, Primitive (14)  ·  Neuroectodermal Tumors (13)  ·  Neoplasms by Site (10)  ·  Sarcoma (10)  ·  Myosarcoma (9)  ·  Neoplasms, Muscle Tissue (9)

Interventions

cixutumumab (3)  ·  Sirolimus (2)  ·  temsirolimus (2)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  CR011-vcMMAE (1)  ·  CTLA-4 Antigen (1)  ·  Colony-Stimulating Factors (1)  ·  Denosumab (1)  ·  HhAntag691 (1)  ·  Imatinib Mesylate (1)  ·  Ipilimumab (1)  ·  Irinotecan (1)  ·  LY3023414 (1)  ·  MLN 8237 (1)  ·  Magnetic Resonance Spectroscopy (1)

Sponsors

National Cancer Institute (NCI) (16)  ·  Children's Oncology Group (4)  ·  Northwestern University (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (22)  ·  Canada (9)  ·  Puerto Rico (7)  ·  Australia (2)  ·  New Zealand (1)

Top investigators

Brenda Weigel, MD (1)  ·  Brigitte Widemann (1)  ·  Crystal L Mackall (1)  ·  Emily G Greengard (1)  ·  Jeffrey Morgan (1)  ·  Julia Glade-Bender (1)  ·  Katherine A Janeway (1)  ·  Lars Wagner (1)  ·  Lisa Bomgaars (1)  ·  Lisa M Kopp (1)  ·  Mark Agulnik (1)  ·  Mason Bond (1)  ·  Michael Isakoff (1)  ·  Mrinal Gounder (1)  ·  Orren Beaty (1)

Results publications

PMID 31401903, PMID 22347360, PMID 23477833, PMID 30777875, PMID 31586757, PMID 32192573, PMID 34435684, PMID 38520670, PMID 38815151, PMID 39298716

NIH funding

U10CA098543 (8), U10CA180886 (8), P30CA008748 (2), UM1CA097452 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00100 (1), N01CM62206 (1), P30CA060553 (1), U01CA062490 (1), U01CA069856 (1)